These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27763720)

  • 1. Diabetes News.
    Dove AE; Marathe PH; Gao HX; Odeh SA; Close KL
    J Diabetes; 2017 Feb; 9(2):111-114. PubMed ID: 27763720
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drugs in type 2 diabetes mellitus therapy].
    Kvapil M
    Vnitr Lek; 2013 Aug; 59(8):713-8. PubMed ID: 24007229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 5. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
    Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity Week 2016 Annual Meeting.
    Marathe PH; Dove AE; Gao HX; Odeh SA; Close KL
    J Diabetes; 2017 Mar; 9(3):215-218. PubMed ID: 27883282
    [No Abstract]   [Full Text] [Related]  

  • 7. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as "incretin mimetics" that can enhance your blood glucose control.
    Clark WL
    Diabetes Self Manag; 2006; 23(1):36, 39-40. PubMed ID: 16453919
    [No Abstract]   [Full Text] [Related]  

  • 10. Exenatide in combination therapy: small study, big market, and many unanswered questions.
    Malozowski S
    Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355
    [No Abstract]   [Full Text] [Related]  

  • 11. Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.
    Zimmermann J
    Am Fam Physician; 2016 Dec; 94(12):1014-1015. PubMed ID: 28075091
    [No Abstract]   [Full Text] [Related]  

  • 12. Antihyperglycemic medications for cardiovascular disease risk reduction.
    Goldman JD
    Am J Manag Care; 2018 Aug; 24(13 Suppl):S273-S278. PubMed ID: 30160394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
    Hurren KM; Dunham MW
    Expert Opin Pharmacother; 2018 Jul; 19(10):1087-1095. PubMed ID: 29958007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M; Bajaj M
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
    Kaul S
    Circulation; 2016 Jul; 134(2):94-6. PubMed ID: 27400894
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
    Gerstein H; Jaeschke R
    Pol Arch Med Wewn; 2016 Oct; 126(10):803-805. PubMed ID: 27872459
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery for diabetes at lower BMI: some caution.
    Deitel M
    Obes Surg; 2008 Oct; 18(10):1211-4. PubMed ID: 18758867
    [No Abstract]   [Full Text] [Related]  

  • 19. Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
    Kumana CR; Tan KCB; Cheung BMY
    Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975
    [No Abstract]   [Full Text] [Related]  

  • 20. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.